Trial reportPharmacology research & perspectives2026
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects.
Trial report in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects.Pharmacology research & perspectives · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
JKN2306 is a novel, highly selective Nav1.8 inhibitor under development for the treatment of acute pain. This first-in-human study aimed to evaluate its safety, tolerability, pharmacokinetics, and food effect (FE). This was a single center, randomized, double-blind, placebo controlled, single ascending dose (SAD) and FEstudy in healthy Chinese subjects. In the SAD part, 44 subjects were randomized to receive a single oral dose of JKN2306 (10, 30, 100, 200, or 400 mg) or placebo. The FE part was a sequential, two-period crossover study in 14 subjects from the 200 mg SAD cohort, who received a single 200 mg dose under fasting and fed conditions. Forty-four subjects were enrolled and completed the study. JKN2306 was safe and well-tolerated across all doses. Treatment-emergent adverse events were mostly Grade 1, with no serious adverse events or dose limiting toxicities. No clinically significant effects on QTc interval were observed. JKN2306 was rapidly absorbed, with T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.